Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …

Lung cancer accounts for a quarter of all cancer deaths. Non-small cell lung cancer
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …

In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …

Detection of molecular aberrations driving the biology and the clinical behavior of advanced
non-small cell lung cancer (NSCLC) allows the adoption of specific therapeutic strategies …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Personalized therapy based on actionable molecular markers has completely transformed
the therapeutic landscape in advanced non–small cell lung cancer (NSCLC). In less than 15 …

The discovery that a number of aberrant tumorigenic processes and signal transduction
pathways are mediated by druggable protein kinases has led to a revolutionary change in …

Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …

In the last 6 years, since the first reports of an association between somatic mutations in
epidermal growth factor receptor (EGFR) exons 19 and 21 and response to EGFR tyrosine …

The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …